Institutional shares held 1.95 Million
0 calls
0 puts
Total value of holdings $43.5M
$0 calls
$0 puts
Market Cap $761M
34,470,400 Shares Out.
Institutional ownership 5.66%
# of Institutions 8


Latest Institutional Activity in KNSA

Top Purchases

Q3 2024
Harbor Capital Advisors, Inc. Shares Held: 97.5K ($2.15M)
Q2 2024
Advisor Group Holdings, Inc. Shares Held: 623 ($13.8K)
Q2 2024
Cwm, LLC Shares Held: 451 ($9.96K)
Q1 2024
Hhlr Advisors, Ltd. Shares Held: 3.14M ($69.2M)
Q1 2024
Braidwell LP Shares Held: 1.39M ($30.8M)

Top Sells

Q2 2024
Barclays PLC Shares Held: 34.8K ($769K)
Q1 2024
Rubric Capital Management LP Shares Held: 2.2M ($48.5M)
Q1 2024
Millennium Management LLC Shares Held: 239K ($5.29M)
Q1 2024
Goldman Sachs Group Inc Shares Held: 760K ($16.8M)
Q1 2024
Pictet Asset Management Holding Sa Shares Held: 1.46M ($32.3M)

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.


Insider Transactions at KNSA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
722K Shares
From 15 Insiders
Grant, award, or other acquisition 23.4K shares
Exercise of conversion of derivative security 699K shares
Sell / Disposition
741K Shares
From 12 Insiders
Payment of exercise price or tax liability 39.3K shares
Open market or private sale 702K shares

Track Institutional and Insider Activities on KNSA

Follow Kiniksa Pharmaceuticals, Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA